Abstract
ADHD is a neurodevelopmental disorder associated with significant morbidity and mortality that affects 5% of children, adolescents and adults worldwide. Pharmacological and behavioral therapies exist, but critical symptoms such as dysexecutive deficits remain unaffected. In this randomized, placebo-controlled, double-blind, cross-over study we assess the cognitive and physiological effects of tDCS in adult ADHD patients in order to understand (1) the role of DLPFC laterality in ADHD dysexecutive deficits, (2) the physiological dynamics sustaining the modulation of executive function by tDCS, and (3) the impact of state-dependent dynamics of tDCS effect. The participants consisted of a random sample of 40 adult patients with a primary diagnosis of ADHD. Each patient performed three experimental sessions in which they received 30 minutes of 2mA tDCS stimulation targeting the left DLPFC (anodal F3, cathodal Fp2), the right DLPFC (anodal F4, cathodal Fp1) and Sham. Before and after each session, half of the patients completed the Flanker task (EFT) and the other half performed the Stop Signal Task (SST), while we assessed cognitive (reaction time, accuracy) and neurophysiological measures (EEG Event-Related-Potentials). Results show that anodal tDCS to the left DLPFC modulated cognitive (reaction time) and physiological measures (P300 amplitude) in the Flanker task in a state-dependent manner, but there were no significant effects in the Stop Signal Reaction Time of the SST. We interpret these results as an improvement in interference cognitive control (captured by the EFT) but not in action cancellation (assessed by the SST), supporting the hypothesis of the existence of different impulsivity constructs with overlapping but distinct anatomical substrates and therapeutic strategies. We conclude that anodal tDCS over the left DLPFC using a simple bipolar montage has pro-cognitive effects in dysexecutive patients with ADHD associated with the modulation of physiological signatures of cognitive control (i.e. treatment target), supporting specific hypotheses and strategies for neuromodulation treatment development under an experimental therapeutics framework aiming to link target engagement (cognitive and physiological) with clinical benefit. In addition, we also provide empirical evidence supporting the value of the P200, N200 and P300 as cross-sectional biomarkers of cognitive performance across tasks. Last, we provide mechanistic support for the state-dependent nature of the effects of tDCS, highlighting the importance of controlling the neural states before and during stimulation as a relevant therapeutic strategy.
Competing Interest Statement
GR is a co-founder of Neuroelectrics, a company that manufactures the tDCS technology used in the study. LDV is an employee at Neuroelectrics. JAC is a member of the scientific advisory board for Apex Neuroscience Inc. AW has patent applications pending related to cognitive enhancement through brain stimulation and new methods of transcranial electrical stimulation. CS reports that, within the past 12 months, he has received research support from Shire/Takeda Pharmaceuticals, has served as a consultant to Adlon, Shire, Sunovion, Supernus and Teva pharmaceuticals, and has received book royalties for “Fast Minds – How to Thrive If You Have ADHD [or Think You Might],” as well as “ADHD in Adults – A Practical Guide to Evaluation and Management”. The remaining authors declare no competing financial interests.
Clinical Trial
NCT04175028
Funding Statement
This research was partly supported by NIH grants (RO1 MH112737, R21 DA042271, R21 AG056958 and R21 MH115280) to JAC.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available upon reasonable request to the senior author (JAC).
